Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Key Highlights
- ➤Phase 1/2 study opens enrollment for vopimetostat plus ERAS-0015
- ➤Trial targets MTAP-deleted pancreatic ductal adenocarcinoma patients
- ➤Trial targets MTAP-deleted, RAS-mutant non-small cell lung cancer patients
- ➤Dose escalation will determine the combination’s maximum tolerated dose
- ➤ERAS-0015 showed responses across multiple RAS-mutant tumor types in early data
Expert Statements
Malte Peters, President and CEO of Tango Therapeutics
“The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers.”
Malte Peters, President and CEO of Tango Therapeutics
“We are thrilled to initiate this study in partnership with Erasca, a company leading the advancement of RAS-targeted therapies, to evaluate vopimetostat with ERAS-0015 and further explore the potential of this clinically validated and synergistic combination approach.”
Jonathan E. Lim, Chairman, CEO, and co-founder of Erasca
“Pairing ERAS-0015’s pan-RAS inhibition with vopimetostat’s PRMT5 inhibition creates a complementary, dual-targeted approach with the potential for deeper, more durable responses in patients with these difficult-to-treat cancers.”
Jonathan E. Lim, Chairman, CEO, and co-founder of Erasca
“We are excited to work closely with Tango, a leader in the development of PRMT5-targeted therapies, to advance this promising combination and evaluate its potential to deliver meaningful benefit for patients with pancreatic and lung cancers, where new treatment options are urgently needed.”
BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer and Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) is now open for enrollment.
“The encouraging clinical activity, durability and tolerability observed to date with vopimetostat in combination with RAS inhibition reinforce our belief that co-targeting PRMT5 and RAS represents a promising new frontier in the treatment of pancreatic cancer and potentially other RAS-driven cancers,” said Malte Peters, M.D., President and CEO of Tango Therapeutics. “We are thrilled to initiate this study in partnership with Erasca, a company leading the advancement of RAS-targeted therapies, to evaluate vopimetostat with ERAS-0015 and further explore the potential of this clinically validated and synergistic combination approach.”
Get started
Create a free account to read the full story.